External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. - Wikidata - awgldk - TriplyDB

External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

http://www.wikidata.org/entity/Q35040836

about

Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C.Evaluation of the association of sleep apnea-related systemic inflammation with CRP, ESR, and neutrophil-to-lymphocyte ratio.Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis.High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma.Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma.Rare long-term survivors of pancreatic adenocarcinoma without curative resection.Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.Comparison of preoperative neutrophil-lymphocyte, lymphocyte-monocyte, and platelet-lymphocyte ratios in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy.Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.Association of the Derived Neutrophil-Lymphocyte Ratio With Critical Limb Ischemia.Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy.Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases.The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up.The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan.May ratio of neutrophil to lymphocyte be useful in predicting the risk of developing preeclampsia? A pilot study.Can Neutrophil/Lymphocyte Ratio be a Predictor for Bone Metastases of Solid Tumors?Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib.The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies.Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma Oxidative stress in healthy pregnancy and preeclampsia is linked to chronic inflammation, iron status and vascular function

P2860

Q28083684-62A514CE-5683-44FD-84F1-BB91FD734AA3 Q28542043-9BF41493-CB7A-4A01-B957-4DB8DAD58777 Q33613637-05C10B50-79A1-4056-85A4-217CC32F2943 Q33624392-FC8F09C0-917F-417E-8974-3124CE60C699 Q34628015-B69B9025-099E-41C5-B234-3AC238A91EC1 Q35105057-042795FA-BC40-4789-BE49-194922F000D0 Q35881343-1AC97226-9512-411C-92CA-212FD0D562C7 Q35905788-4A261299-BFF5-49FD-8D42-D69E5CCED7F2 Q35936126-BA9EB585-F710-446E-AA73-8A8081AD5CBC Q35984951-3315CC76-A1D1-4B8F-9E81-78ACA6CCBB4B Q36184759-EB3763DB-40B0-4D5E-83D1-A3FB9DCD509B Q36186701-9BEB1997-A042-46BE-AC48-E6F93FFFEBAD Q36401628-2EE8C7BF-6E03-49DA-BCFE-7B3818E1533F Q36825610-11DB654F-AAD3-4C55-A260-60B52CCD392F Q37129614-9004827E-47BA-4624-B123-57A22F313C95 Q37525286-5117A695-3D2F-4B13-B00C-ADF04FDEACD8 Q37725511-B7235818-D8D9-46E7-BE20-B4CB3EB5BAE4 Q38811369-DACBF192-A5ED-4C5C-A6AB-60CC894D8B0C Q38902180-D0AE0880-0FC9-43F4-9F0A-A9051533A344 Q38980174-4D164CDA-52CF-46FC-AEB4-8E576D4F2194 Q39093002-95AD2BEC-55A0-430D-964C-2F4652A6D0CE Q39138898-F4BF6039-7FC9-4423-B1F3-662763AB0025 Q40502145-3D8AC3AE-413C-4627-9A03-EAF88C234C7A Q40510647-B3318771-B679-4FAD-B63A-F9992D2C127F Q40853317-54410722-27A5-4AD5-94A9-82346CFB56D1 Q41002124-2E24F256-2398-487B-BC30-0BF066D792E0 Q41162196-D0F9868E-F25A-478F-9195-F55EB4D32EE5 Q41996520-791C7027-BDCC-4567-9E6C-16114F39EF2F Q42674196-23E7C224-141E-43C1-A78A-BA3BFA3E7523 Q44317521-D872B414-246C-49A7-A8E9-1D53F2C17E2B Q44372438-CD1C4724-8D74-4BC3-A302-8D5D74792825 Q47109054-68978C8A-DE2D-43B6-95E5-8FC8ADC27153 Q47135359-57C52981-6D3F-4A9B-A020-F3D22D49834D Q48936608-D4438CB3-07CD-4DFF-9A1A-CD95853CF0AA Q52691760-811EF610-4B7C-4E91-9938-F72AF2EAC538 Q53548609-60029021-B153-4389-8F08-38D20920FB77 Q58698478-02B6F65B-3BC3-42D2-8F22-84DEC64AA3BE Q58751124-FD809879-F4B9-4F87-8213-E9978EB51CAE Q58752248-205C8C97-C747-45D0-AACD-47254774617C

P2860

External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

http://www.wikidata.org/entity/Q35040836

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

External validation of the der ...... of pancreatic cancer patients.

@ast

External validation of the der ...... of pancreatic cancer patients.

@en

type

label

External validation of the der ...... of pancreatic cancer patients.

@ast

External validation of the der ...... of pancreatic cancer patients.

@en

prefLabel

External validation of the der ...... of pancreatic cancer patients.

@ast

External validation of the der ...... of pancreatic cancer patients.

@en

P1433

Q35040836-D401DBD1-5811-4632-9669-57D2E82293D2

P1476

Q35040836-F63A588E-66DB-46A5-9EBB-8FF4246B114F

P2093

Q35040836-226B0DAD-E45C-4A3C-93D8-B210E41E91E1

Q35040836-3382A4B7-D0B2-494F-8D8B-A517EB9A78A6

Q35040836-3A44D88E-3126-4E1D-8A90-6CB5EA3C3656

Q35040836-477F6644-AEF5-4FFD-8AE5-13BC78797FA2

Q35040836-5ADAD969-594A-475A-817B-C598ABEB3ED1

Q35040836-689D5166-CDE7-4A3F-B6C2-A19D71063794

Q35040836-71B91632-BCCE-4177-B45B-E530DF763735

Q35040836-9D69471E-74F1-4CC7-90F5-FE2962399855

Q35040836-A2B4E68A-B43E-43B8-80EF-AEBBEDE003A8

Q35040836-A6FC887D-5204-4857-B0AA-8CD87F45313F

P2860

Q35040836-066E6602-67DE-4C01-8FF3-857E15CCC130

Q35040836-0EDD03B4-E4A1-4150-A829-133872DD7962

Q35040836-156072E4-6931-4472-B210-08AC03CF5685

Q35040836-2C94ABE3-0941-4C2E-ABA9-2FDE459BBC58

Q35040836-37ABA679-0208-45DC-ACB7-0CBC176932AA

Q35040836-3AAB0B84-EE83-4660-A28D-7A918C09926A

Q35040836-3E23BB95-E36C-42C7-8925-B034F0E87096

Q35040836-3E906256-E947-4EB3-A0DA-37491AC4F8E2

Q35040836-55D5DCA5-3717-40ED-9F55-7E6CBEB49F20

Q35040836-6885A208-1B53-465C-82CA-AF6D29961F19

P304

Q35040836-14CC808E-02EB-4781-9F5D-A781AE033C07

P31

Q35040836-35193F84-D735-46B0-8D33-180923B70865

P356

Q35040836-B70D2E2C-939E-43CF-97DC-6B9D2BB71BEF

P407

Q35040836-81D2BA49-132E-4B2A-9C72-39828CBEC480

P433

Q35040836-EE77103B-CA23-44AC-9039-7658B8B55608

P478

Q35040836-C041B4B3-7919-41B6-88D1-D01681A4E323

P50

Q35040836-24B294D5-C16E-4E64-979B-5ECEBC7C4FA0

Q35040836-2FA088FB-5283-4A5C-91C2-083B1686C8EF

P577

Q35040836-4A389AB8-FA64-42C0-B52C-B254CCC90C8D

P5875

Q35040836-0D8D8220-1B1D-460A-A7DA-07916DECE538

P698

Q35040836-DD00D348-4166-44B7-84AD-280559D242A6

P932

Q35040836-99A49029-ECAE-4A89-8C48-84A712296B7E

P356

JOURNAL.PONE.0078225

P1433

P1476

External validation of the der ...... of pancreatic cancer patients.

@en

P2093

Anna Lena Ress

http://www.w3.org/2001/XMLSchema#string

Armin Gerger

http://www.w3.org/2001/XMLSchema#string

Florian Eisner

http://www.w3.org/2001/XMLSchema#string

Friederike Sophia Seggewies

http://www.w3.org/2001/XMLSchema#string

Gudrun Absenger

http://www.w3.org/2001/XMLSchema#string

Hellmut Samonigg

http://www.w3.org/2001/XMLSchema#string

Martin Pichler

http://www.w3.org/2001/XMLSchema#string

Michael Stotz

http://www.w3.org/2001/XMLSchema#string

Peter Kornprat

http://www.w3.org/2001/XMLSchema#string

Renate Schaberl-Moser

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Hallmarks of Cancer: The Next Generation

Inflammation and cancer

Cancer statistics, 2012

Cancer-related inflammation

Immunity, Inflammation, and Cancer

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

The immunobiology of cancer immunosurveillance and immunoediting

Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Progress in human tumour immunology and immunotherapy.

P304

e78225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0078225

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Joanna Szkandera

P577

2013-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258504805

http://www.w3.org/2001/XMLSchema#string

P698

24223776

http://www.w3.org/2001/XMLSchema#string

P932

3817201

http://www.w3.org/2001/XMLSchema#string